Aspect Announces General Availability of Aspect Unified IP 7.4 SP1, the Premier Enterprise Contact Center Solution for High Volume Customer Outreach
Today, Aspect announced the general availability of Aspect® Unified IP® and Advanced List Management™ 7.4 SP1, the latest release of its comprehensive, omnichannel customer engagement platform for managing experiences across service, collections and sales. This upgrade provides major enhancements in usability to deliver a modern user experience, making it easier to use for agents, managers and administrators use. The 7.4 SP1 release also builds upon Aspect’s outbound market leadership by adding new capabilities to help customers operate outbound contact centers efficiently, effectively and in compliance with national, regional and local regulations.
“Aspect Unified IP is the premier inbound and outbound enterprise contact center solution available in the market, and has been for over 14 years. The world’s top brands depend on Unified IP every day, and we are committed to continued development and offering new capabilities to help companies build lifetime loyalty among their consumers,” said Michael Harris, Chief Product Officer and CMO at Aspect.
Aspect Unified IP and Advanced List Management deliver advanced customer engagement capabilities that drive profitability and customer loyalty for many of the largest enterprises in financial, communications, retail, healthcare, and customer service around the world. Aspect remains committed to building upon and maintaining this essential platform. This release features improvements to the user interface such as:
- Improves the user interface for agents, managers and administrators into a consolidated, intuitive design across a variety of functions
- Provides managers, supervisors and administrators an improved user experience with quicker access to configuration tools, real-time data and alerts
- Refreshing third party tech so customers can stay current with security, compliance and IT protocols
“Aspect Unified IP provides best-in-class functionality and uptime for our entire organization including collections, customer service, back office, loan origination, and service desk. It is both an effective and efficient solution for our contact center and customer engagement needs,” said Michael Montgomery, VP Contact Center Solutions Exeter Finance
In the face of a global recession, the importance of outbound dialing and collections will steadily rise across industries. Aspect offers the only comprehensive outbound contact center solutions that allow the world’s largest organizations to effectively conduct proactive outreach activities while maintaining compliance with complicated regional, local, and national regulatory requirements. Aspect Unified IP and Advanced List Management are well equipped to help organizations adapt to the new challenges posed by this recession, and with the 7.4 SP1 release, additional capabilities have been added to ALM’s extensive tool set such as:
- Functionality to help improve operational efficiency, allowing organizations to smooth out dialing and reach more customers in a shorter period of time
- Goal-driven rules to ensure dialing aligns with an overall outreach strategy
- Security and auditing features to help maintain compliance with relevant regulations
- The ability to play specific messages for each attempt, creating more effective customer experiences while improving operational efficiency by minimizing repeat interactions
“City of Mesa has been on the Aspect Unified IP platform for six-plus years now since upgrading from legacy Aspect CallCenter® ACD. Like its predecessor, it has been a rock solid/stable platform in support of both standard hours and 24x7 services. The ease of being able to stand up new departments on the platform for remote workers during this time has proven to be invaluable,” said Richard Sandoval, Senior Unified Communications Engineer City of Mesa.
FIND OUT MORE about Aspect Unified IP and Advanced List Management.
About Aspect
Aspect is on a mission to simplify and improve customer engagement. Our enterprise software is used by millions of agents every year and supports billions of consumer interactions around the world. Our best-of-breed contact center and workforce optimization applications help companies keep agents engaged while providing exceptional customer service experiences. Our flexible, highly scalable solutions for self-service and live interaction management and workforce optimization are available on-premises or in any hosted, private or public cloud environment.
For more information, visit www.aspect.com. Follow Aspect on Twitter at @AspectSoftware. Read our blogs at http://blogs.aspect.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005568/en/
Contact information
Michael Harris, Aspect Software CMO
602-586-5810
press.inquiry@aspect.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom